Andres Brendan, Taleban Sasha
Internal Medicine, University of Arizona College of Medicine - Tucson, Tucson, USA.
Gastroenterology and Hepatology, University of Arizona College of Medicine - Tucson, Tucson, USA.
Cureus. 2022 Sep 28;14(9):e29718. doi: 10.7759/cureus.29718. eCollection 2022 Sep.
Ustekinumab inhibits interleukins 12 and 23 and modulates the T helper cell-mediated immune response of Crohn's disease. However, ustekinumab may also exacerbate atopic disease by increasing the T helper 2 cell-mediated pathway. We present the first known case of exacerbation of atopic dermatitis in a patient with Crohn's disease receiving ustekinumab. Additional associations in dose frequency, peripheral eosinophilia, and elevated serum IgE were observed. However, while novel in Crohn's disease, exacerbation of atopy after ustekinumab infusion has been observed in patients with psoriasis and psoriatic arthritis.
乌司奴单抗可抑制白细胞介素12和23，并调节克罗恩病中辅助性T细胞介导的免疫反应。然而，乌司奴单抗也可能通过增强辅助性T2细胞介导的途径而加重特应性疾病。我们报告了首例接受乌司奴单抗治疗的克罗恩病患者出现特应性皮炎加重的已知病例。观察到在剂量频率、外周血嗜酸性粒细胞增多和血清IgE升高方面存在其他关联。然而，虽然在克罗恩病中是新发现的，但在银屑病和银屑病关节炎患者中已观察到输注乌司奴单抗后特应性加重的情况。
